利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.012 秒)

    Gastroresistant pharmaceutical formulations for oral administration containing bile acids
    2.
    发明公开
    Gastroresistant pharmaceutical formulations for oral administration containing bile acids 失效
    胃液稳定的药物制剂的胆汁酸口服Verbreichung。

    公开(公告)号：EP0509335A1

    公开(公告)日：1992-10-21

    申请号：EP92105716.2

    申请日：1992-04-02

    申请人： ALFA WASSERMANN S.p.A.

    发明人： Marchi, Egidio ,  Tamagnone, Gianfranco ,  Rotini, Leone Gabriele

    IPC分类号： A61K31/575 ,  A61K9/28

    CPC分类号： A61K9/4808 ,  A61K9/2009 ,  A61K9/2886 ,  A61K9/4858 ,  A61K9/4891 ,  A61K31/575

    摘要： Pharmaceutical formulations for oral administration coated by an enterosoluble gastroresistant film, preferably selected from gastroresistant granulates, gastroresistant tablets, gastroresistant hard gelatine capsules containing powders or granulates or two or more tablets or oily suspensions, gastroresistant soft gelatine capsules containing oily suspensions and hard gelatine capsules containing gastroresistant granulates or two or more gastroresistant tablets, containing therapeutically effective amounts of bile acids mixed with physiologically compatible basic substances which favour bile acids salification and therefore bile acids absorption in the intestinal tract, process for their preparation and therapeutic use thereof in the treatment of biliary calculoses, biliary dyspepsias, biliary cirrhosis and chronic and cholestatic hepatopathies.

    摘要翻译： 用于通过在肠溶肠溶电影涂覆口服给药的药物制剂，优选肠溶颗粒剂，肠溶片剂，肠溶硬明胶胶囊含有粉剂或颗粒剂或两种或更多种片剂或油性悬浮液，胃液的软明胶胶囊含有油性悬浮液和硬明胶胶囊包含选择 肠溶颗粒剂或两种或多种肠溶片剂，包含与生理上相容的碱性物质混合的胆汁酸的治疗有效量在有利于胆汁酸成盐，因此在肠道胆汁酸的吸收，处理为他们在胆道的治疗及其制备方法和治疗用途 calculoses，胆道消化不良，胆汁性肝硬化，慢性胆汁淤积和hepatopathies。

    Gastroresistant pharmaceutical formulations for oral administration containing salts of bile acids
    5.
    发明公开
    Gastroresistant pharmaceutical formulations for oral administration containing salts of bile acids 失效
    包含用于口服给药的肠溶药物组合物，胆汁盐。

    公开(公告)号：EP0510404A1

    公开(公告)日：1992-10-28

    申请号：EP92105714.7

    申请日：1992-04-02

    申请人： ALFA WASSERMANN S.p.A.

    发明人： Marchi, Egidio ,  Tamagnone, Gianfranco ,  Rotini, Leone Gabriele

    IPC分类号： A61K31/575 ,  A61K9/28

    CPC分类号： A61K31/575 ,  A61K9/2886 ,  A61K9/4808 ,  A61K9/4891

    摘要： Pharmaceutical formulations for oral administration coated by an enterosoluble gastroresistant film, preferably selected from gastroresistant granulates, gastroresistant tablets, gastroresistant hard gelatine capsules containing powders or granulates or two or more tablets or oily suspensions, gastroresistant soft gelatine capsules containing oily suspensions and hard gelatine capsules containing gastroresistant granulates or two or more gastroresistant tablets, containing therapeutically effective amounts of salts of bile acids with alkali metals or organic bases, process for their preparation and therapeutic use thereof in the treatment of biliary calculoses, biliary dyspepsias, biliary cirrhosis and chronic and cholestatic hepatopathies.

    摘要翻译： 用于通过在肠溶肠溶电影涂覆口服给药的药物制剂，优选肠溶颗粒剂，肠溶片剂，肠溶硬明胶胶囊含有粉剂或颗粒剂或两种或更多种片剂或油性悬浮液，胃液的软明胶胶囊含有油性悬浮液和硬明胶胶囊包含选择 肠溶颗粒剂或两种或多种肠溶片剂，含有碱金属或有机碱，它们的制备方法和在胆汁calculoses，胆道消化不良，胆汁性肝硬化，慢性和胆汁淤积hepatopathies的治疗及其治疗用途的胆汁酸的盐的治疗有效量 ，

    New galenic formulations with programmed release
    6.
    发明公开
    New galenic formulations with programmed release 失效
    Galenische Formulierungen mit gesteuerter Freigabe。

    公开(公告)号：EP0324981A1

    公开(公告)日：1989-07-26

    申请号：EP88121777.2

    申请日：1988-12-28

    申请人： ALFA WASSERMANN S.p.A.

    发明人： Rotini, Leone Gabriele ,  Marchi, Egidio

    IPC分类号： A61K9/22 ,  A61K9/54 ,  A61K31/19 ,  A61K31/195 ,  A61K31/52

    CPC分类号： A61K31/52 ,  A61K9/2077 ,  A61K9/5084 ,  A61K31/19 ,  A61K31/195

    摘要： New galenic formulations with programmed release, to be administered by oral route, containing as the active ingredient a drug selected from the non steroidal antiinflam­matory, bronchodilator, vasodilator, cardiovascular and muscle relaxant drugs.
    In these new formulations, a portion of the active ingredient is released in a short time, so that the drug can quickly develop its therapeutic action reaching the necessary hematic levels, while the remaining portion of the active constituent is released in a longer interval of time so as to allow the therapeutic coverage till the subsequent adminis­tration. Said therapeutic coverage can even last 24 hours; thus the new galenic formulations object of the present invention are suitable for a once a day administration.

    摘要翻译： 具有程序释放的新的盖仑制剂，通过口服途径施用，作为活性成分含有选自非甾体抗炎药，支气管扩张剂，血管扩张剂，心血管和肌肉松弛药物的药物。 在这些新制剂中，活性成分的一部分在短时间内被释放，使得药物可以快速发展达到必需血液水平的治疗作用，而活性成分的剩余部分在更长的时间间隔内释放 以便允许治疗覆盖直到随后的给药。 所述治疗覆盖甚至可以持续24小时; 因此本发明的新的盖仑制剂制剂的目的适合于每天一次给药。